Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

REV-ERB and ROR nuclear receptors as drug targets

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Kojetin, Douglas
  • Burris, Thomas

publication date

  • March 2014

journal

  • Nature Reviews Drug Discovery  Journal

abstract

  • The nuclear receptors REV-ERB (consisting of REV-ERBα and REV-ERBβ) and retinoic acid receptor-related orphan receptors (RORs; consisting of RORα, RORβ and RORγ) are involved in many physiological processes, including regulation of metabolism, development and immunity as well as the circadian rhythm. The recent characterization of endogenous ligands for these former orphan nuclear receptors has stimulated the development of synthetic ligands and opened up the possibility of targeting these receptors to treat several diseases, including diabetes, atherosclerosis, autoimmunity and cancer. This Review focuses on the latest developments in ROR and REV-ERB pharmacology indicating that these nuclear receptors are druggable targets and that ligands targeting these receptors may be useful in the treatment of several disorders.

subject areas

  • Animals
  • Atherosclerosis
  • Diabetes Mellitus
  • Drug Delivery Systems
  • Humans
  • Ligands
  • Neoplasms
  • Nuclear Receptor Subfamily 1, Group D, Member 1
  • Nuclear Receptor Subfamily 1, Group F, Member 1
  • Receptors, Cytoplasmic and Nuclear
  • Receptors, Retinoic Acid
  • Signal Transduction
scroll to property group menus

Identity

PubMed Central ID

  • PMC4865262

International Standard Serial Number (ISSN)

  • 1474-1776

Digital Object Identifier (DOI)

  • 10.1038/nrd4100

PubMed ID

  • 24577401
scroll to property group menus

Additional Document Info

start page

  • 197

end page

  • 216

volume

  • 13

issue

  • 3

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support